TuHURA Biosciences (NASDAQ:HURA - Get Free Report) was upgraded by equities research analysts at Brookline Capital Management to a "strong-buy" rating in a report released on Monday,Zacks.com reports. Brookline Capital Management also issued estimates for TuHURA Biosciences' Q2 2025 earnings at ($0.15) EPS, Q3 2025 earnings at ($0.15) EPS, Q4 2025 earnings at ($0.15) EPS, FY2025 earnings at ($0.60) EPS, FY2026 earnings at ($0.58) EPS, FY2027 earnings at ($0.57) EPS, FY2028 earnings at ($0.43) EPS and FY2029 earnings at $0.08 EPS.
Other analysts have also recently issued research reports about the stock. HC Wainwright restated a "buy" rating and issued a $12.00 target price on shares of TuHURA Biosciences in a research note on Friday, May 16th. Wall Street Zen cut TuHURA Biosciences from a "hold" rating to a "sell" rating in a research report on Saturday, June 14th. One equities research analyst has rated the stock with a sell rating, three have assigned a buy rating and two have issued a strong buy rating to the company's stock. According to data from MarketBeat, the stock has an average rating of "Buy" and a consensus price target of $12.67.
View Our Latest Report on TuHURA Biosciences
TuHURA Biosciences Trading Down 5.1%
TuHURA Biosciences stock traded down $0.12 during midday trading on Monday, hitting $2.23. 327,129 shares of the company's stock were exchanged, compared to its average volume of 243,989. TuHURA Biosciences has a 12-month low of $1.80 and a 12-month high of $7.93. The firm's 50 day simple moving average is $3.39 and its 200 day simple moving average is $3.72.
TuHURA Biosciences (NASDAQ:HURA - Get Free Report) last announced its earnings results on Thursday, May 15th. The company reported ($0.15) earnings per share for the quarter, missing the consensus estimate of ($0.13) by ($0.02).
Hedge Funds Weigh In On TuHURA Biosciences
A number of large investors have recently bought and sold shares of the business. Geode Capital Management LLC bought a new position in shares of TuHURA Biosciences in the fourth quarter valued at approximately $1,084,000. Apollon Wealth Management LLC raised its holdings in TuHURA Biosciences by 86.0% during the first quarter. Apollon Wealth Management LLC now owns 114,926 shares of the company's stock worth $371,000 after purchasing an additional 53,154 shares in the last quarter. Northern Trust Corp acquired a new stake in shares of TuHURA Biosciences in the fourth quarter valued at $234,000. Squarepoint Ops LLC acquired a new position in TuHURA Biosciences during the fourth quarter worth about $223,000. Finally, Hurlow Wealth Management Group Inc. bought a new stake in shares of TuHURA Biosciences in the 4th quarter worth approximately $170,000. Institutional investors own 0.62% of the company's stock.
TuHURA Biosciences Company Profile
(
Get Free Report)
TuHURA Biosciences, Inc NASDAQ: HURA is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. TuHURA's lead innate immune response agonist candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors.
Recommended Stories
Before you consider TuHURA Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and TuHURA Biosciences wasn't on the list.
While TuHURA Biosciences currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
